Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-18 · Built: 2026-10-18 · 中文

← United States · Coverage record

US · SEC FORM 4

Tyra Biosciences, Inc.

TYRA · Nasdaq · CIK 0001863127 · Healthcare · Biotechnology

INSIDER SIGNAL

45.0 / 100

1 buyers · 1 purchase transaction lines · $20.0K gross purchase

WHY THIS SIGNAL?

Buyer breadthLow
Purchase sizeLow
RoleStrong
RecencyModerate
ConvictionStrong
Score anatomy

Each bar shows the contribution to the current score; the weights and formula stay unchanged.

Cluster+7.0 / 35
Purchase size+2.8 / 25
Role+20.0 / 20
Recency+5.2 / 10
Conviction+10.0 / 10

What is holding the score back?

  • ⚠ Cluster breadth is moderate · 1 insider(s), not 4+
  • ⚠ Purchase size is modest relative to the model scale
  • ✓ Role scores high · most senior buyer: Director

Purchase-size comments are relative to the model scale. Average daily volume is a separate market-context diagnostic.

US-v1.2 ranks qualifying equity purchases under the current 180-day rules. The score is a research priority, not a return forecast or probability. Backtests have not shown that a higher US score is followed by better returns.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
Fuhrman AlanChief Financial Officer
○○
Harris ToddPresident and CEO
○○
Rueb YuliyaVice President, Finance (PAO)
○○
Warner Douglas JChief Medical Officer
○
Ashar BhaveshChief Operating Officer
○
Verjee RehanDirector
●
● Purchase▼ Sale○ Other

—

Purchase breadth & concentration

QUALIFYING BUYERS1
PURCHASE CONCENTRATION100%Largest buyer: Verjee Rehan · $20.0K
CLUSTER BUYING · 15D1 insiderPeak activity: 2026-09-09–2026-09-09

Roles in the peak window: Director. Concentration uses priced qualifying P lines only and does not change the saved score.

SIGNAL HISTORY

45.0 / 100

Latest recorded score

↓ -0.2 ptsversus the previous recorded snapshot
  1. 45.5
  2. 45.4
  3. 45.3
  4. 45.2
  5. 45.0

Only scores saved when a full US scoring run completed are shown; gaps are not reconstructed.

Recent Form 4 activity

1Purchases
14Sales
13Other Form 4 lines
19SEC filings · 365 days
BUYING1 qualifying P line(s) · 180 days
SELLING0 sale line(s) · context only
OTHER8 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot assessed

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context provides additional background on recent price performance and risk. It does not affect the Insider Signal.

Price performance

1M
-15.3%
3M
-39.0%
6M
-43.4%
12M
+46.3%

Volatility & liquidity

Volatility
66.9%
Beta
—
Avg daily value
USD 17.1M

Valuation

Market cap
USD 1.2B
P/E
—

Fundamentals

Profit margin
—
ROE
-46.3%
Industry
Biotechnology

Market data

Price data up to: 2026-10-11 · Price source: OpenBB/yfinance; volume from price cache (yfinance) · From SEC filings: Market cap, ROE · Fiscal year ended: 2025-12-31 · Market cap is the shares outstanding stated on the filing cover multiplied by the latest close. Share count date: 2026-07-31 · Status: PASS

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
9,414,018
Previous report
9,876,964
Avg daily volume
1,066,287
Days to cover
8.8

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting ownerTypeSecuritySharesAvg. priceApprox. valueSource
2026-09-09Verjee RehanPurchase (P)Common Stock972USD 20.58USD 20,001SEC filing ↗
2025-06-16Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund, L.P.; Shah Rajeev M.Purchase (P)Common Stock11,813USD 10.13USD 119,666SEC filing ↗
2025-06-13Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund, L.P.; Shah Rajeev M.Purchase (P)Common Stock120,167USD 10.20USD 1,225,703SEC filing ↗
2025-06-12Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund, L.P.; Shah Rajeev M.Purchase (P)Common Stock31,307USD 10.20USD 319,331SEC filing ↗
2025-06-09Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund, L.P.; Shah Rajeev M.Purchase (P)Common Stock186,850USD 10.19USD 1,904,002SEC filing ↗
2025-06-05Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund, L.P.; Shah Rajeev M.Purchase (P)Common Stock213,334USD 10.04USD 2,141,873SEC filing ↗
2025-06-04Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund, L.P.; Shah Rajeev M.Purchase (P)Common Stock997,864USD 9.63USD 9,609,430SEC filing ↗
2024-11-08Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund, L.P.; Shah Rajeev M.Purchase (P)Common Stock1,220,681USD 16.25USD 19,836,066SEC filing ↗
2024-10-30Fuhrman AlanPurchase (P)Common Stock9,500USD 16.00USD 152,000SEC filing ↗
2021-12-17Boxer Asset Management Inc.; Boxer Capital, LLC; LEWIS JOSEPHPurchase (P)Common Stock125,000USD 13.12USD 1,640,000SEC filing ↗
2021-09-17Chen Bihua; Cormorant Asset Management, LP; Cormorant Global Healthcare Master Fund, LP; Cormorant Private Healthcare Fund III LPPurchase (P)Common Stock312,500USD 16.00USD 5,000,000SEC filing ↗
2021-09-17MORE ROBERT JPurchase (P)Common Stock156,250USD 16.00USD 2,500,000SEC filing ↗
2021-09-17Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund, L.P.; Shah Rajeev M.Purchase (P)Common Stock1,250,000USD 16.00USD 20,000,000SEC filing ↗
2021-09-17Boxer Asset Management Inc.; Boxer Capital, LLC; Davis Aaron I.; LEWIS JOSEPH; MVA Investors, LLCPurchase (P)Common Stock625,000USD 16.00USD 10,000,000SEC filing ↗
2021-09-17Alta Partners NextGen Fund II Management, LLC; Alta Partners NextGen Fund II, L.P.; Hudson Peter A; JANNEY DANIELPurchase (P)Common Stock156,250USD 16.00USD 2,500,000SEC filing ↗

Form 4 evidence

28 transaction lines in the latest 365-day window; 248 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-09-15Rueb YuliyaAward / grant (A)Common Stock2,925USD 9.13USD 26,705SEC filing ↗
2026-09-15Harris ToddAward / grant (A)Common Stock864USD 9.13USD 7,888SEC filing ↗
2026-09-15Fuhrman AlanAward / grant (A)Common Stock951USD 9.13USD 8,683SEC filing ↗
Show recent Form 4 evidence (25 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-09-15Rueb YuliyaAward / grant (A)Common Stock2,925USD 9.13USD 26,705SEC filing ↗
2026-09-15Harris ToddAward / grant (A)Common Stock864USD 9.13USD 7,888SEC filing ↗
2026-09-15Fuhrman AlanAward / grant (A)Common Stock951USD 9.13USD 8,683SEC filing ↗
2026-09-09Verjee RehanPurchase (P)Common Stock972USD 20.58USD 20,001SEC filing ↗
2026-05-05Warner Douglas JAward / grant (A)Common Stock25,000USD 0.00USD 0SEC filing ↗
2026-05-05Rueb YuliyaAward / grant (A)Common Stock8,333USD 0.00USD 0SEC filing ↗
2026-05-05Harris ToddAward / grant (A)Common Stock79,000USD 0.00USD 0SEC filing ↗
2026-05-05Fuhrman AlanAward / grant (A)Common Stock20,000USD 0.00USD 0SEC filing ↗
2026-05-05Ashar BhaveshAward / grant (A)Common Stock15,013USD 0.00USD 0SEC filing ↗
2026-03-26KAPLAN GILLAOption exercise / conversion (M)Common Stock53,172USD 2.25USD 119,637SEC filing ↗
2026-03-26KAPLAN GILLAD (D)Common Stock53,172USD 37.75USD 2,007,243SEC filing ↗
2026-03-25KAPLAN GILLASale (S)Common Stock14,295USD 36.97USD 528,486SEC filing ↗
2026-03-25KAPLAN GILLAOption exercise / conversion (M)Common Stock14,295USD 2.25USD 32,164SEC filing ↗
2026-03-13Harris ToddAward / grant (A)Common Stock1,463USD 9.13USD 13,357SEC filing ↗
2026-03-13Fuhrman AlanAward / grant (A)Common Stock1,376USD 9.13USD 12,563SEC filing ↗
2026-02-12Bensen DanielSale (S)Common Stock8,000USD 32.87USD 262,981SEC filing ↗
2026-01-12Bensen DanielSale (S)Common Stock8,000USD 28.52USD 228,171SEC filing ↗
2025-12-19MORE ROBERT JSale (S)Common Stock10,000USD 25.00USD 250,000SEC filing ↗
2025-12-12Bensen DanielSale (S)Common Stock8,000USD 22.64USD 181,120SEC filing ↗
2025-11-21MORE ROBERT JSale (S)Common Stock246,871USD 20.25USD 4,999,138SEC filing ↗
2025-11-19Bensen DanielSale (S)Common Stock49,956USD 16.32USD 815,282SEC filing ↗
2025-11-18Bensen DanielSale (S)Common Stock75,633USD 16.07USD 1,215,422SEC filing ↗
2025-11-17Bensen DanielSale (S)Common Stock20,072USD 16.18USD 324,800SEC filing ↗
2025-11-14Bensen DanielSale (S)Common Stock110,228USD 16.02USD 1,765,853SEC filing ↗
2025-11-13Bensen DanielSale (S)Common Stock1,111USD 16.00USD 17,776SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-18
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerTYRA
CIK0001863127
SectorHealthcare
IndustryBiotechnology Yahoo Finance
SEC SIC2834 Pharmaceutical Preparations
ExchangeNasdaq

Data coverage

Local Form 4 history248 transaction lines from 2021-09-17 to 2026-09-15
15 P purchase lines · 134 S sale lines · 99 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.